25
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prevalence and behavioural risks for HIV and HCV infections in a population of drug users of Dakar, Senegal: the ANRS 12243 UDSEN study

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Objectives

          Data on the extent of drug use and associated HIV, hepatitis C and hepatitis B infection in West Africa are lacking. The objectives of ANRS12244 UDSEN study were to estimate the size of the heroin and/or cocaine drug user (DU) population living in the Dakar area (Senegal), and assess the prevalence and risk factors of HIV, hepatitis C virus (HCV) and hepatitis B virus (HBV), including behavioural determinants in this population, in order to set up an integrated prevention and treatment programme for DUs.

          Design and methods

          A capture-recapture method was applied for population size estimation, whereas the respondent-driven sampling (RDS) method was used to recruit a sample of DUs living in the Dakar area and determine HIV, HBV and HCV prevalence. Behavioural data were gathered during face-to-face interviews, and blood samples were collected on dried blood spots for analysis in a central laboratory. Data analysis was performed using the RDS analysis tool, and risk factors were determined by logistic regression. Access to laboratory results was organized for the participants.

          Results

          The size of the DU population in the Dakar area was estimated to reach 1324 (95% confidence interval (95% CI: 1281–1367)). Based on the 506 DUs included in the study, the HIV, HCV and HBV prevalence were 5.2% (95% CI: 3.8–6.3), 23.3% (95% CI: 21.2–25.2) and 7.9% (95% CI: 5.2–11.1), respectively. In people who inject drugs (PWID), prevalence levels increased to 9.4% for HIV and 38.9% for HCV ( p=0.001 when compared to those who never injected). Women were more at risk of being HIV infected (prevalence: 13.04% versus 2.97% in males, p=0.001). Being PWID was a risk factor for HCV and HIV infection (odds ratio, OR: 2.7, 95% CI: 1.7–4.3, and OR: 4.3, 95% CI: 1.7–10.7, respectively), whereas older age and female sex were additional risk factors for HIV infection (10% increase per year of age, p=0.03 and OR: 4.9, 95% CI: 1.6–156, respectively). No specific determinant was associated with the risk of HBV infection.

          Conclusions

          High HIV and HCV prevalence were estimated in this population of DUs (including non-injectors) living in the Dakar area, Senegal, whereas HBV prevalence was close to that of the global Senegalese population, reflecting a risk of infection independent of drug use. Women seem to be highly vulnerable and deserve targeted interventions for decreasing exposure to HIV, while behavioural risk factors for HIV and HCV include the use of unsafe injections, reflecting the urgent need for developing harm reduction interventions and access to opioid substitution therapy services.

          Related collections

          Most cited references24

          • Record: found
          • Abstract: found
          • Article: not found

          HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.

          Previous reviews have examined the existence of HIV prevention, treatment, and care services for injecting drug users (IDUs) worldwide, but they did not quantify the scale of coverage. We undertook a systematic review to estimate national, regional, and global coverage of HIV services in IDUs. We did a systematic search of peer-reviewed (Medline, BioMed Central), internet, and grey-literature databases for data published in 2004 or later. A multistage process of data requests and verification was undertaken, involving UN agencies and national experts. National data were obtained for the extent of provision of the following core interventions for IDUs: needle and syringe programmes (NSPs), opioid substitution therapy (OST) and other drug treatment, HIV testing and counselling, antiretroviral therapy (ART), and condom programmes. We calculated national, regional, and global coverage of NSPs, OST, and ART on the basis of available estimates of IDU population sizes. By 2009, NSPs had been implemented in 82 countries and OST in 70 countries; both interventions were available in 66 countries. Regional and national coverage varied substantially. Australasia (202 needle-syringes per IDU per year) had by far the greatest rate of needle-syringe distribution; Latin America and the Caribbean (0.3 needle-syringes per IDU per year), Middle East and north Africa (0.5 needle-syringes per IDU per year), and sub-Saharan Africa (0.1 needle-syringes per IDU per year) had the lowest rates. OST coverage varied from less than or equal to one recipient per 100 IDUs in central Asia, Latin America, and sub-Saharan Africa, to very high levels in western Europe (61 recipients per 100 IDUs). The number of IDUs receiving ART varied from less than one per 100 HIV-positive IDUs (Chile, Kenya, Pakistan, Russia, and Uzbekistan) to more than 100 per 100 HIV-positive IDUs in six European countries. Worldwide, an estimated two needle-syringes (range 1-4) were distributed per IDU per month, there were eight recipients (6-12) of OST per 100 IDUs, and four IDUs (range 2-18) received ART per 100 HIV-positive IDUs. Worldwide coverage of HIV prevention, treatment, and care services in IDU populations is very low. There is an urgent need to improve coverage of these services in this at-risk population. UN Office on Drugs and Crime; Australian National Drug and Alcohol Research Centre, University of New South Wales; and Australian National Health and Medical Research Council. Copyright 2010 Elsevier Ltd. All rights reserved.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            EXTENSIONS OF RESPONDENT-DRIVEN SAMPLING: ANALYZING CONTINUOUS VARIABLES AND CONTROLLING FOR DIFFERENTIAL RECRUITMENT

              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              The association between HIV infection and alcohol use: a systematic review and meta-analysis of African studies.

              To summarize the association between alcohol use and human immunodeficiency virus (HIV) infection based on studies conducted in Africa, EMBASE and PubMed were searched for African studies that related alcohol use to HIV infection. Meta-analyses were conducted to obtain pooled univariate and multivariate relative risk estimates. Subgroup analyses were performed for studies having different sample types: males or females and population-based or high-risk, and ones that differentiated between problem and asymptomatic drinkers. Alcohol drinkers were more apt to be HIV+ than nondrinkers. The pooled unadjusted odds ratio (OR) from 20 studies was 1.70 (95% confidence interval, CI = 1.45-1.99). Results from 11 studies that adjusted for other risk factors produced a pooled risk estimate of 1.57 (95% CI = 1.42-1.72). Males and females had similar risk estimates, while studies involving high-risk samples tended to report larger pooled odds ratios than studies of the general population. When compared with nondrinkers, the pooled estimates of HIV risk were 1.57 (95% CI = 1.33-1.86) for non-problem drinkers versus 2.04 (95% CI = 1.61-2.58) for problem drinkers, a statistically significant difference (z = 2.08, P <0.04). Alcohol use was associated with HIV infection in Africa and alcohol-related interventions might help reduce further expansion of the epidemic.
                Bookmark

                Author and article information

                Journal
                J Int AIDS Soc
                J Int AIDS Soc
                JIAS
                Journal of the International AIDS Society
                International AIDS Society
                1758-2652
                22 May 2015
                2015
                : 18
                : 1
                : 19888
                Affiliations
                [1 ]Institut Médecine Epidémiologie Appliquée, Université Xavier Bichat, Paris, France
                [2 ]Hôpital Psychiatrique de Thiaroye, Dakar, Senegal
                [3 ]Sorbonne-Universités, Paris, France
                [4 ]Service de Maladies Infectieuses et Tropicales, Hôpitaux Universitaires de l'Est Parisien, Hôpital Saint-Antoine, Paris, France
                [5 ]Inserm UMR-S1136, Institut Pierre-Louis de Santé Publique, Paris, France
                [6 ]Centre Régional de Recherche et de Formation à la Prise en Charge Clinique (CRCF), Service des Maladies Infectieuses, Centre Hospitalier Universitaire de Fann, Dakar, Sénégal
                [7 ]Laboratoire de Bacterio-virologie, Hôpital Le Dantec, Dakar, Senegal
                [8 ]Laboratoire de Virologie, Hôpitaux Universitaires de l'Est Parisien, Hôpital Saint-Antoine, Paris, France
                [9 ]Département Santé, Expertise France, Paris, France
                Author notes
                [§ ] Corresponding authors: Annie Leprêtre, Institut de Médecine et d'Epidémiologie Appliquée, Université Xavier Bichat, 16 rue Henri Huchard, FR-75018 Paris, France. Tel: +33 1 39 59 71 71. Fax: +33 1 39 59 71 71. ( anlepretre@ 123456gmail.com ); Karine Lacombe, Service de Maladies Infectieuses et Tropicales, Hôpital Saint-Antoine, 184 rue du Fbg Saint-Antoine, FR-75012 Paris, France. Tel: +33 1 49283137. Fax: +33 1 49282149. ( karine.lacombe@ 123456sat.aphp.fr )
                Article
                19888
                10.7448/IAS.18.1.19888
                4442125
                26004637
                aefd5aa8-d1e6-419b-a9e3-9cff1960bc5c
                © 2015 Leprêtre A et al; licensee International AIDS Society

                This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 28 October 2014
                : 24 March 2015
                : 22 April 2015
                Categories
                Research Article

                Infectious disease & Microbiology
                human immunodeficiency virus,hepatitis c virus,hepatitis b virus,drug use,senegal,respondent-driven sampling

                Comments

                Comment on this article